Wang, Z., Zhong, J., Duan, J., Zhao, J., Wang, Z., Zhuo, M., Zhou, C., Li, Z., Yi, X., Chang, J., Jin, S., Wu, D., Song, Q., Dong, X., Ma, L., Jin, B., Lv, D., Liu, Z., Wang, L., Wang, J. (2026). Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba101